Michael Shiloh, M.D., Ph.D.

Michael Shiloh, M.D., Ph.D.

  • Professorship in Infectious Diseases, in honor of James P. Luby, M.D.
  • Internal Medicine - Infectious Diseases and Geographic Medicine

Biography

Tuberculosis is a global epidemic that annually accounts for approximately 2 million deaths worldwide. Because of the capacity of Mycobacterium tuberculosis (Mtb) to establish a latent infection, an estimated 1-2 billion people worldwide are infected with Mtb. Because of this, my long-term goal is to discover the mechanisms by which Mtb causes disease in humans.  My laboratory is taking an integrated approach, using powerful new molecular genetic, cell biologic, bioinformatic and metabolomic tools to test novel hypotheses and challenge existing paradigms. Our ultimate aim is to use this knowledge to develop new vaccines and treatments for Mtb.

Three key phases in a pathogen’s life cycle dictate its ability to cause disease, namely, i) invasion ii) survival and propagation and iii) escape beyond the host to infect naïve individuals. To date, how Mtb crosses the mucosa and enters the human body is incompletely understood. Likewise, the full repertoire of mechanisms used by Mtb to manipulate and persist within host macrophages is unknown. Additionally, our knowledge of macrophage antimicrobial mechanisms in host defense against Mtb and other pathogens remains incomplete. Enhancing such antimicrobial mechanisms via host-directed therapies is a promising new approach to Mtb treatment. Finally, how Mtb facilitates its own transmission through cough induction has not been studied. Thus, we are addressing these areas of Mtb biology through a series of hypothesis-driven approaches. First, how does Mtb penetrate the nasopharyngeal and respiratory mucosa to cause disease? Second, what are the mechanisms Mtb uses to manipulate host processes to facilitate survival? Third, can host antimicrobial pathways be leveraged to enhance the eradication of intracellular bacteria such as Mtb? Finally, how does Mtb trigger coughing to mediate its spread?

See More

Education & Training
  • Medical School - Cornell University Medical College (1993-2001)
  • Residency - University of California, San Francisco (2001-2003), Internal Medicine
  • Fellowship - University of California at San Francisco (2003-2007), Infectious Diseases
Professional Associations & Affiliations
  • American Association of Immunologists (2014)
  • American Society of Microbiology (2013)
  • Infectious Disease Society of America (2010)
Honors & Awards
  • The Department of Internal Medicine Chair’s Pilot Awards 2015-2017, A Synthetic Lethal Genetic Interaction Map in Mycobacterium tuberculosis
  • UTSW High Impact/High Risk Award 2012, Research award for development of a novel M. tuberculosis vaccine
  • Disease Oriented Clinical Scholar, UTSW 2011
  • NIH/NIAID K08 award 2008, 2008-2012
  • Sandler Family Foundation Discovery Award 2006, Research award for highly innovative research
  • Giannini Family Foundation Research Fellowship, 2005-2008 2005, Honors research fellows in the state of California
  • Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases 2018-2023
Books & Publications
Research
  • Innate immune response to intracellular pathogens
  • Microbial pathogenesis
  • Mucosal immunology
  • Mycobacterium tuberculosis
  • Role of carbon monoxide (CO) in host-pathogen interactions